Literature DB >> 3961523

Case report 350: Multiple myeloma--blastic type.

R R Edelman, H Kaufman, G M Kolodny.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3961523     DOI: 10.1007/bf00350212

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


× No keyword cloud information.
  5 in total

1.  Bone sclerosis in multiple myeloma.

Authors:  E P ENGELS; R C SMITH; S KRANTZ
Journal:  Radiology       Date:  1960-08       Impact factor: 11.105

2.  Bone sclerosis in multiple myeloma.

Authors:  G Evison; K T Evans
Journal:  Br J Radiol       Date:  1967-02       Impact factor: 3.039

3.  Increased skeletal:renal uptake ratio: etiology and characteristics.

Authors:  T H Cheng; B L Holman
Journal:  Radiology       Date:  1980-08       Impact factor: 11.105

4.  Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients.

Authors:  R Bataille; J Chevalier; M Rossi; J Sany
Journal:  Radiology       Date:  1982-12       Impact factor: 11.105

5.  Bone scintigraphy in the diagnosis of skeletal involvement and metastatic calcification in multiple myeloma.

Authors:  H Nilsson-Ehle; C Holmdahl; M Suurküla; J Westin
Journal:  Acta Med Scand       Date:  1982
  5 in total
  4 in total

1.  Case report 646. POEMS syndrome.

Authors:  W Bessler; F Antonucci; B Stamm; G Stuckmann; T Vollrath
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

2.  Osteosclerotic myeloma variants.

Authors:  F M Hall; S M Gore
Journal:  Skeletal Radiol       Date:  1988       Impact factor: 2.199

3.  Multiple myeloma presenting as extramedullary plasmacytoma of the thyroid, advanced grade II-III plasmablastic type.

Authors:  V L Schiller; A L Deutsch; R R Turner
Journal:  Skeletal Radiol       Date:  1995-05       Impact factor: 2.199

4.  Cystic angiomatosis of bone with sclerotic changes mimicking osteoblastic metastases.

Authors:  T Ishida; H D Dorfman; G C Steiner; A Norman
Journal:  Skeletal Radiol       Date:  1994-05       Impact factor: 2.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.